Sermorelin vs Tesamorelin — same receptor, very different regulatory status
Sermorelin and Tesamorelin are both analogues of growth-hormone-releasing hormone and act at the same GHRH receptor. The meaningful difference is not mechanism but status and stability: Tesamorelin is a stabilised analogue that exists as an FDA-approved prescription drug for a specific indication, while Sermorelin does not hold that approval. Any comparison that treats them as two research chemicals of equal standing is missing the point.
Most comparisons of these two argue about which produces a stronger response. That framing skips the distinction that actually governs how each one can be sold, advertised and handled.
Same receptor, different molecules
| Sermorelin | Tesamorelin | |
|---|---|---|
| Class | GHRH analogue | GHRH analogue |
| Receptor | GHRH receptor | GHRH receptor |
| Structure | Shorter analogue of the native releasing hormone | Stabilised analogue carrying a structural modification |
| Regulatory status | No FDA approval | FDA-approved for a specific indication |
Why the regulatory line matters commercially
An approved drug is treated differently by advertising platforms, payment processors and marketplaces. Google Merchant Center, for one, refuses listings for approved pharmaceuticals outright — which is why Tesamorelin is excluded from our product feed while other compounds are not. None of that is a statement about the molecule. It is a statement about the category the molecule sits in.
What the comparison cannot tell you
- Head-to-head research is scarce. Most published work studies one analogue against control, not against the other.
- Stability is not potency. Resistance to degradation is a property of the molecule, and inferring a stronger effect from it is an extrapolation.
- Approval is indication-specific. An approved drug is approved for one defined use, which says nothing about any other use.
- Neither status implies research-material quality. That is settled by the certificate of analysis, not the regulatory category.
The compounds discussed here
Go deeper
Frequently asked questions
- Do Sermorelin and Tesamorelin act on the same receptor?
- Yes. Both are analogues of growth-hormone-releasing hormone and engage the GHRH receptor. That is why they are grouped together, and it is also why the comparison is usually framed as though the only difference were potency.
- Is Tesamorelin an approved drug?
- Tesamorelin is approved by the FDA for a specific indication under a brand name. Sermorelin does not hold that approval. This is a legal and regulatory distinction, not a quality one, and it changes how each compound is treated in every commercial context including advertising and payment processing.
- Why is Tesamorelin described as stabilised?
- Native GHRH is degraded rapidly. Tesamorelin carries a structural modification intended to resist that degradation. Sermorelin is a shorter analogue of the native hormone without that modification, which is the structural basis for treating them as distinct rather than interchangeable.
References
Primary literature for the compounds above. Links open the record on PubMed.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Falutz J, et al. J Acquir Immune Defic Syndr. 2010. PMID 20101189 → · summary
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV Falutz J, et al. N Engl J Med. 2007. PMID 18057338 → · summary
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency Prakash A, et al. BioDrugs. 1999. PMID 18031173 → · summary
- Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children Thorner M, et al. J Clin Endocrinol Metab. 1990. PMID 2140733 → · summary